Oncolytics Biotech (ONCY) Prepaid Assets (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Prepaid Assets of $1.1 million for Q4 2025, down 20.78% year-over-year from $1.3 million in Q4 2024, and down 10.57% quarter-over-quarter from $1.2 million in Q3 2025.
Oncolytics Biotech (ONCY) Prepaid Assets (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Prepaid Assets for 17 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Prepaid Assets fell 20.78% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $1.1 million (down 20.78% YoY), while the FY2025 annual figure was $1.1 million, down 18.4% from the prior year.
- Prepaid Assets slipped to $1.1 million in Q4 2025 per ONCY's latest filing, from $1.2 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $4.5 million in Q2 2023 and bottomed at $826151.2 in Q3 2024.
- Historically, Prepaid Assets has averaged $2.5 million across 5 years, with a median of $2.3 million in 2025.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 58.55% — and 2024, when it tumbled 76.56%.
- Oncolytics Biotech's Prepaid Assets stood at $2.2 million in 2021, then gained by 1.19% to $2.2 million in 2022, then rose by 6.99% to $2.4 million in 2023, then slumped by 43.41% to $1.3 million in 2024, then decreased by 20.78% to $1.1 million in 2025.
- Business Quant data shows ONCY's Prepaid Assets at $1.1 million in Q4 2025, $1.2 million in Q3 2025, and $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.74 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 826,151.19 |
| Jun 30, 2024 | 2.46 Mn |
| Mar 31, 2024 | 2.27 Mn |
| Dec 31, 2023 | 2.38 Mn |
| Sep 30, 2023 | 3.53 Mn |
| Jun 30, 2023 | 4.53 Mn |
| Mar 31, 2023 | 2.86 Mn |
| Dec 31, 2022 | 2.23 Mn |
| Sep 30, 2022 | 4.10 Mn |
| Jun 30, 2022 | 4.21 Mn |
| Mar 31, 2022 | 3.12 Mn |
| Dec 31, 2021 | 2.20 Mn |
| Sep 30, 2021 | 2.59 Mn |
| Jun 30, 2021 | 3.66 Mn |